SNDX - CIK 0001395937
The table below shows Syndax Pharmaceuticals Inc's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $130.89M | $116.81M | $108.64M | $153.99M | $133.02M | $105.40M |
| Short-term investments | $221.17M | $319.17M | $346.60M | $358.20M | $256.59M | $319.70M |
| Receivables | - | - | - | - | - | - |
| Inventory | $34.95M | $25.00M | $17.70M | $4.66M | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $471.18M |
| $529.83M |
| $531.68M |
| $548.75M |
| $414.81M |
| $446.06M |
| Property, plant & equipment | $177.00K | $128.00K | $0.00 | $0.00 | $0.00 | $2.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $472.67M | $551.79M | $596.15M | $640.71M | $425.81M | $476.95M |
| Accounts payable | $10.84M | $13.83M | $17.35M | $10.05M | $4.90M | $11.57M |
| Total current liabilities | $86.17M | $114.19M | $112.99M | $94.55M | $59.38M | $42.47M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $431.05M | $436.36M | $438.73M | $425.65M | $59.38M | $42.61M |
| Retained earnings | -$1.55B | -$1.44B | -$1.38B | -$1.31B | -$1.13B | -$1.04B |
| Total equity | $41.62M | $115.43M | $157.42M | $215.06M | $366.43M | $434.34M |